A delegation led by Thomas Bohn, CEO of the Swiss West Economic Development Agency, visited Hualan Shares. The two sides held in-depth discussions on Hualan Shares' investment in the Natural Constant project, the global layout of pharmaceutical packaging materials, and the strategic development of AI in pharmaceuticals. The Swiss West Economic Development Agency expressed that it will provide comprehensive official service support for Hualan Shares' investment implementation in Switzerland, and assist in connecting with Swiss and European industrial resources. Hualan Shares' management accompanied the guests on a tour of the intelligent production factory, where its smart manufacturing level and quality control system were highly recognized. This exchange marks the formal establishment of a regular communication channel between the two sides, kicking off a new chapter of two-way empowerment cooperation between the Chinese and Swiss pharmaceutical industries.
Jiangsu Hualan New Pharmaceutical Material Co. Ltd.Discussions on global pharmaceutical packaging layout and AI pharma strategy with Swiss agency support may expand end-customer demand.